106 F.3d 838 (8th Cir. 1996)
When he was three years old, Jason Enos was taking an asthma medication called theophylline. Jason suffered seizures and severe brain damage.1 In 1983, his mother Cheryl sued Jason's doctors for malpractice. Jason's attorneys asked Dr. Miles Weinberger, a theophylline authority, for his opinion on the cause of Jason's seizures.2 Dr. Weinberger found fault with Jason's doctors, but said the seizures probably were not caused by theophylline. The parties settled. In exchange for $900,000, both Cheryl and Jason's father David Enos signed a broadly worded release.3
In 1995, David Enos brought this action on Jason's behalf against Key Pharmaceuticals, Inc., and Pfizer, Inc., producers of theophylline under the respective brand names Theo-Dur and Sustaire.4 David's claims include products liability, fraud, and misrepresentation. Key and Pfizer moved for summary judgment, asserting in defense the release David signed.5 The district court granted the motion, and David appeals.6
The case was submitted on November 18, 1996, and the opinion was filed on February 10, 1997, by the United States Court of Appeals for the Eighth Circuit.7 The panel consisted of Circuit Judges Fagg, Lay, and Hansen, with the opinion authored by Circuit Judge Fagg.8
Whether the broadly worded release signed by Jason Enos's parents bars the products liability, fraud, and misrepresentation claims against Key Pharmaceuticals, Inc. and Pfizer, Inc.?9
In South Dakota as elsewhere, a release is a contract.10 In construing a contract, courts must give effect to the intent of the parties, which is found in the contract's language.11 The instrument Cheryl and David signed released both Jason's doctors and all other persons, firms, corporations, or entities who are or might be liable from any and all actions, causes of action, claims, demands, damages of every kind, character and description, including, but not limited to, such allegedly on account of, or in any way growing out of, personal injuries and property damage resulting, or to result, from the alleged negligence and malpractice of Defendants or others.12 David signed a general release.13
Yes. The release executed by Cheryl and David Enos in exchange for $900,000 was a general release that by its plain terms released all entities from all claims of every kind, not limited to negligence and malpractice claims.14 This bars the products liability, fraud, and misrepresentation claims brought by David Enos on Jason's behalf against the producers of theophylline.15
The district court properly granted summary judgment on this basis after Key and Pfizer asserted the release in defense.16
The broadly worded release bars the products liability, fraud, and misrepresentation claims against Key Pharmaceuticals, Inc. and Pfizer, Inc.17
Whether South Dakota public policy as expressed in South Dakota Codified Laws section 53-9-3 prohibits enforcement of the release against nonparties to the contract?18
South Dakota Codified Laws section 53-9-3 provides that all contracts which have for their object, directly or indirectly, to exempt anyone from responsibility for his own fraud or willful injury to the person or property of another are against the policy of the law.19 The district court concluded section 53-9-3 applies only to the parties to a contract, not to nonparties like Key or Pfizer.20 The public policy of South Dakota favors assertion of release by nonparties to the release contract.21
No. Section 53-9-3 does not prohibit enforcement of the release in favor of Key Pharmaceuticals, Inc. and Pfizer, Inc. Neither company was a party to the release or a fiduciary of Jason or David Enos.2223 The public policy favors the assertion of the release by these nonparties.24
The statute therefore provides no basis to set aside the release against the theophylline producers.25
South Dakota public policy does not prohibit enforcement of the release against nonparties to the contract.26
Whether Key Pharmaceuticals, Inc. and Pfizer, Inc. are equitably estopped from relying on the release based on the conduct of Dr. Miles Weinberger?27
For equitable estoppel to apply against Key and Pfizer, Jason must have been deceived by Key and Pfizer.28 Dr. Weinberger's conduct is irrelevant unless in his dealings with Jason's attorneys, the doctor acted as Key's and Pfizer's agent.29 Although David contends Dr. Weinberger had a financial interest in Key, David has not asserted facts that, taken as true, would establish the doctor was Key's agent.30
No. Key and Pfizer cannot be equitably estopped from relying on the release.31 Jason must have been deceived by Key and Pfizer, but Dr. Weinberger was not shown to be their agent.32 The elements of an agency relationship are not met by the facts presented.33
Equitable estoppel therefore does not prevent summary judgment based on the release.34
Key Pharmaceuticals, Inc. and Pfizer, Inc. are not equitably estopped from relying on the release based on the conduct of Dr. Miles Weinberger.35